These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34003613)

  • 1. Current pharmacotherapy of overactive bladder.
    Kreydin EI; Gomes CM; Cruz F
    Int Braz J Urol; 2021; 47(6):1091-1107. PubMed ID: 34003613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
    Fogaing C; Mossa AH; Campeau L
    Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
    Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
    J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating vibegron for the treatment of overactive bladder.
    Rechberger T; Wróbel A
    Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.
    Dmochowski RR; Rovner ES; Kennelly MJ; Newman DK; Abedinzadeh L; Snyder D; Thomas E; Haag-Molkenteller C; Rosenberg MT
    BMC Urol; 2023 Apr; 23(1):64. PubMed ID: 37095473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
    Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
    Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comprehensive pharmacologic management of overactive bladder].
    Krivoborodov GG; Tur EI
    Urologiia; 2017 Apr; (1):82-88. PubMed ID: 28394529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence.
    Özkidik M; Coşkun A; Asutay MK; Bahçeci T; Hamidi N
    Int Braz J Urol; 2019; 45(4):782-789. PubMed ID: 31136113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
    Giarenis I; Robinson D; Cardozo L
    Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.